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Ildikó Kalina1 and Pál Novák Kaposi1Abstract
We report the palliative embolization and functional imaging follow-up of a recurrent shoulder plasmacytoma.
The multiple myeloma patient complained of severe pain and discomfort, while he could not tolerate further
chemotherapy. The left shoulder lesion had earlier received a high dose of irradiation. Thus, the well-vascularized
lesion was embolized via feeding arteries branching off from the left subclavian artery in two sessions. The
patient’s symptoms rapidly improved post-embolization and the serum free light chain ratio stabilized at a lower
level. The follow-up magnetic resonance image showed increased diffusivity in previously restricted tumor foci.
This has negatively correlated with the decreased fludeoxyglucose uptake on PET, suggesting post-embolization
necrosis.
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The first results for the selective transcatheter arterial
embolization (TAE) of bone tumors were reported in
1975 [1]. Since then, TAE has been successfully used to
control symptoms in patients with either primary or
metastatic disease. Nevertheless, TAE does not have a
role in the standard treatment of plasma cell lesions. In
the few reports available, TAE has been performed in se-
lected cases of solitary bone plasmacytomas to reduce the
risk of bleeding during surgical resection [2,3]. Here we re-
port that TAE promptly reduced pain and discomfort in a
patient with a recurrent plasma cell tumor in the left
shoulder. We chose TAE because the patient had already
received the maximum dose of local irradiation and could
not tolerate further chemotherapy. Functional studies, in-
cluding diffusion weighted magnetic resonance imaging
(MRI) with background subtraction (DWIBS) as well as* Correspondence: berczi@hotmail.com
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PET), are recent additions to the imaging of multiple mye-
loma (MM) [4,5]. We utilized both techniques during the
follow-up, and detected excellent conspicuity of the post-
embolization response.Case presentation
A 58-year-old man was first diagnosed with solitary plas-
macytoma of the left scapula 19 years ago. At the time he
was treated with radiation therapy. The tumor had recurred
multiple times, for which a total dose of 38 Gy of local ir-
radiation was administered. A second lesion occurred in
the right acetabulum. Afterwards, the patient was treated
with multiple cycles of combination chemotherapy, and
twice with autologous stem cell transplantation (Additional
file 1: Table S1). In spite of all therapeutic efforts, the dis-
ease did not go into full remission. During the last episode
of recurrence, after two cycles of effective salvage with a
VDT-PACE combination (bortezomib-dexamethason-thal-
idomide-cisplatine-doxorubicine-cyclophosphamide-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bérczi et al. World Journal of Surgical Oncology 2014, 12:271 Page 2 of 4
http://www.wjso.com/content/12/1/271etopozide), the regimen had to be stopped due to the sus-
tained thrombocytopenia.
The patient continued to complain of significant pain,
and restricted movements of the upper limb. Computed
tomography (CT) and MRI scans showed a multifocal
tumor in the left scapula, which extended into the axilla
thus, surgical resection was impossible. At this point, we
decided to use TAE to achieve fast control of the patient’s
symptoms. Angiography showed the lesion was well vas-
cularized (Figure 1A). Embolization of the lesion was per-
formed in two sessions; feeding arteries branching off
from the left subclavian artery were selectively catheter-
ized from a right femoral puncture and a left brachial
puncture, and the tumor vessels were embolized to sta-
sis (Figure 1B) with 350 to 550 μm Contour® PVA parti-
cles (Boston Scientific, Natick, MA, USA). Intravenous
pethidine was administered for analgesia. The plateletFigure 1 Post-embolization tumor response in the shoulder plasmacy
studies. (A) Angiogram of the left shoulder revealed a well-vascularized le
(B) Selective catheterization of the feeding arteries and embolization of the
in two sessions from a right femoral puncture and a left brachial puncture,
DWIBS MRI proved to be a sensitive modality for locating densely packed f
ADC maps with T2 weighted images that allowed more precise compariso
values by 4 weeks post-embolization was clearly visible on the fusion map
PET-CT. (F) Following embolization, decreased metabolic activity was detec
tumor necrosis.count was 161 K at the time of the procedure. We nei-
ther observed bleeding nor any neurological deficit in
association with the embolization. The post-procedural
period was uneventful; and the patient was released to
home on the next day.
The baseline and the consecutive MRI examinations
were performed on a 3 T Philips Achieva scanner (Philips
Healthcare, Eindhoven, the Netherlands) using DWIBS
(b = 0, 800, 1300) and contrast enhanced sequences. The
lesion’s size remained stable after the embolization. Mean-
while, DWIBS showed increasing diffusivity in some
previously diffusion restricted tumor foci (Figure 1C,D).
We co-registered ADC maps with T2 weighted images,
and identical regions of interest (ROI) were drawn
around representative tumor areas for quantitative ana-
lysis (Additional file 2: Figure S1). PET-CT showed low
ADC areas had overlapped with metabolic hot spotstoma could be best demonstrated with functional imaging
sion, which was supplied by branches from the left subclavian artery.
tumor vasculature with 350 to 500 μm PVA particles were performed
respectively. Some arterial branches were also closed off with coils.
oci of tumor cells inside a heterogeneous lesion. (C) We co-registered
n between baseline and follow-up scans. (D) The increase of ADC
. (E) Some DWIBS restricted foci also showed high 18FDG uptake on
ted, which was inversely correlated with increased diffusivity, a sign of
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embolization. Interestingly, there was a negative correl-
ation between decreasing metabolic activity and increasing
diffusivity in these areas (Figure 1E,F), indicating cell loss.
Serum electrophoresis showed monoclonal free light-
chain κ (FLCκ) levels had also regressed (Table 1).
At follow-ups, the patient reported only moderate dis-
comfort and occasional use of pain medication, and
remained relatively symptom free for 6 months. Unfor-
tunately, after temporary improvement, the plasmacy-
toma became again symptomatic and required additional
chemotherapy by 14 months.
Conclusions
Plasma cell tumors are highly radiation sensitive; thus,
radiotherapy is the primary choice of treatment [6]. Occa-
sionally, surgery is combined with radiotherapy to prevent
pathological fractures, or to remove a lesion completely.
Distant bone lesions and bone marrow involvement may
indicate progression to MM. These cases require systemic
chemotherapy or stem cell transplantation. Although pal-
liative TAE can be performed for both primary and meta-
static bone tumors, this technique is rarely used to treat
myeloma lesions. In a couple of cases, solitary bone plas-
macytomas have been embolized pre-operatively to reduce
bleeding [2,3].
In our patient, the left shoulder region had already re-
ceived a high dose of irradiation. Combination salvage
chemotherapy had to be stopped after the second cycle as
the patient developed severe thrombocytopenia and poly-
neuropathy. The tumor diffusely infiltrated the scapula as
well as the axilla; therefore, a surgical consultation deemed
the lesion non-resectable.
We contemplated that TAE could provide quick local
control of the patient’s symptoms. Embolization with PVA
microspheres is a well-established palliative technique.
The rationale of selective TAE is to inject small thrombo-
genic particles into tumor arterioles causing ischemic ne-
crosis and reducing micro-bleeding, thus reducing
symptoms [7]. An angiogram showed a well-vascularized
tumor suitable for embolization. TAE was also readilyTable 1 Results of serum electrophoresis
Clinical status Follow-up time (weeks) FLCκ (mg/l)b k/λ ratiob
Baseline 0 4570 4009
Chemotherapya 11 145 NA
Pre-embolization 28.5 913 78.7
Post-embolization 31 349 8.18
Control 35 350 36.57
The characteristic free kappa light-chain (FLCκ) level returned close to the
normal range after embolization.
aThe test was taken following two cycles of VDT-PACE chemotherapy.
bThe normal range is 3.3 to 19.4 mg/l for FLCκ and 0.26 to 1.95 for the
k/λ ratio.available in our institution, the risk of complications was
minimal and embolization did not preclude other thera-
peutic efforts.
The results of the embolization were apparent on
radiologic follow-ups. The lesion’s size remained stable.
Meanwhile, a partial response was detected with func-
tional studies. MRI is a frequently used morphologic
imaging modality for MM specifically, to detect bone-
marrow involvement. DWIBS is a sensitive tool, which
can identify highly cellular myeloma lesions, as they
characteristically show restricted diffusion [4]. According
to a recent study, ADC values in skull tumors inversely
correlate with cellularity and could be used to differenti-
ate between malignant and benign bone lesions [8]. We
found multiple diffusion restricted foci inside the shoul-
der lesion and hypothesized that these corresponded to
nests of viable plasma cells inside a heterogeneous
tumor, although histological samples were not available
for confirmation. Average pre-treatment ADC values in
these foci ranged between 0.7 and 1.0 × 10−3 s/mm2 at
3 T, which is similar to malignant lesions of the skull,
and to metastatic lesions in MM [4,5,8]. Horger et al.
described that DWIBS is not only able to locate intrame-
dullary foci in MM, but can also detect a short-term re-
sponse following chemotherapy [4]. Messiou et al.
reported that ADC values showed a significant increase
for MM bone lesions 4 to 6 weeks after systemic treat-
ment [5]. We confirm that DWIBS can be used to moni-
tor the post-embolization response in plasma cell
lesions, as we observed significantly increased ADC
values in multiple foci. Embolization-induced cell death
and cellular dehydration are the most likely explanation
for the observed diffusivity changes.
18FDG PET is considered the most reliable method for
detecting early treatment response in MM [9]. Interest-
ingly, we found a negative correlation between decreased
FDG uptake and increased diffusivity in some tumor
areas on the follow-up scans. We speculate that the is-
chemia resulted in cell loss, cellular dehydration and low
glucose uptake following embolization. Similar results
were reported in a preliminary study by Byun et al., who
compared 18FDG-PET with diffusion-weighted MRI fol-
lowing neoadjuvant therapy for osteosarcoma [10]. They
found that SUV and ADC were negatively correlated,
while PET and diffusion-weighted MRI predicted the
histological response with similar accuracy.
Clinically, the patient’s symptoms significantly im-
proved following TAE. The decreased serum immuno-
globulin ratio indicated a reduction in the tumor mass.
This was in part the results of the embolization; how-
ever, previous chemotherapy could have also contributed
to the systemic effect. Importantly, the TAE achieved
temporary control of symptoms for almost 6 months.
During this period, the bone marrow reserve could
Bérczi et al. World Journal of Surgical Oncology 2014, 12:271 Page 4 of 4
http://www.wjso.com/content/12/1/271recover, neurotoxicity diminished and administration of
salvage chemotherapy become possible for inducing re-
mission again. In summary, TAE can relieve the acute
pain and discomfort of plasmacytomas. The sensitivity
of DWIBS is comparable to 18FDG-PET for detecting an
early tumor response post-embolization.Consent
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change in diffusivity could be demonstrated in another focus in the
axilla.Abbreviations
18FDG: fludeoxyglucose; CT: computed tomography; DWIBS: diffusion
weighted magnetic resonance imaging with background subtraction;
FLCκ: free light-chain κ; MRI: magnetic resonance imaging; PET: positron
emission tomography; TAE: transcatheter arterial embolization.Competing interests
The authors declare no competing interests.Authors’ contributions
VB conceived the study, carried out the embolization procedures and
approved the manuscript. GR and LRK performed the MRI and DWIBS image
analysis and discussed the manuscript. TG performed the PET-CT imaging.
GM and TM were involved in the clinical follow-up and data collection, and
helped to prepare the manuscript. IK participated in the CT and MRI
reporting. PNK coordinated data collection, participated in image and
statistical analysis and drafted the manuscript. All authors approved the
manuscript.Acknowledgements
The authors thank Dr Zoltán Bánsághi and Dr Péter Reményi for their
participation in patient management, and Dr Ildikó Vietorisz for performing
serum immunoglobulin assays.
Author details
1Department of Radiology and Oncotherapy, Semmelweis University, Üllői út
78/a, H-1082 Budapest, Hungary. 2MRI Research Center, Szentágothai J
Knowledge Center, Budapest, Hungary. 3Department of Nuclear Medicine,
Semmelweis University, Budapest, Hungary. 4Department of Haematology
and Stem Cell Transplantation, St Istvan and St Laszlo Hospital, Budapest,
Hungary. 5Scanomed Ltd, Budapest, Hungary. 6Third Department of Internal
Medicine, Semmelweis University, Budapest, Hungary.
Received: 18 May 2014 Accepted: 6 August 2014
Published: 22 August 2014References
1. Feldman F, Casarella WJ, Dick HM, Hollander BA: Selective intra-arterial
embolization of bone tumors. A useful adjunct in the management of
selected lesions. Am J Roentgenol Radium Ther Nucl Med 1975, 123:130–139.
2. Boos N, Goytan M, Fraser R, Aebi M: Solitary plasma-cell myeloma of the
spine in an adolescent. Case report of an unusual presentation. J Bone
Joint Surg (Br) 1997, 79:812–814.
3. Matsuda M, Nakazawa T, Kizuki H, Matsumura K, Nakasu S, Handa J: Solitary
plasmacytoma of the skull vault – case report. Neurol Med Chir (Tokyo)
1996, 36:388–392.
4. Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M: Whole-body
diffusion-weighted MRI with apparent diffusion coefficient mapping for
early response monitoring in multiple myeloma: preliminary results. Am
J Roentgenol 2011, 196:W790–W795.
5. Messiou C, Giles S, Collins DJ, West S, Davies FE, Morgan GJ, Desouza NM:
Assessing response of myeloma bone disease with diffusion-weighted
MRI. Br J Radiol 2012, 85:e1198–e1203.
6. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A: A review for
solitary plasmacytoma of bone and extramedullary plasmacytoma.
Scientific World J 2012, 2012:895765.
7. Marciel AM, Van Zandt BL, Baxter AJ: Transcatheter arterial embolization
for the palliation of painful bone lesions. Tech Vasc Interv Radiol 2011,
14:141–149.
8. Ginat DT, Mangla R, Yeaney G, Johnson M, Ekholm S: Diffusion-weighted
imaging for differentiating benign from malignant skull lesions and
correlation with cell density. Am J Roentgenol 2012, 198:W597–W601.
9. Agarwal A, Chirindel A, Shah BA, Subramaniam RM: Evolving role of FDG
PET/CT in multiple myeloma imaging and management. Am J Roentgenol
2013, 200:884–890.
10. Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, Jeon DG, Koh JS, Lee
SY, Lim SM: Combination of 18F-FDG PET/CT and diffusion-weighted MR
imaging as a predictor of histologic response to neoadjuvant
chemotherapy: preliminary results in osteosarcoma. J Nucl Med 2013,
54:1053–1059.
doi:10.1186/1477-7819-12-271
Cite this article as: Bérczi et al.: Diffusion weighted magnetic resonance
imaging demonstrates tumor response following palliative embolization
of a recurrent shoulder plasmacytoma. World Journal of Surgical Oncology
2014 12:271.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
